CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo

CG Oncology, Inc.

BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.
Median duration of response 28 months; 58.3% of responders maintained CR at 24 months by K-M.
97.3% of patients free from progression to muscle-invasive bladder cancer at 24 months; 91.6% cystectomy-free.
No Grade 3+ treatment-related adverse events or deaths; median resolution of any TRAE was one day.
Cohort P (Ta/T1 without CIS): 90.5% high-grade recurrence-free survival at 3 and 9 months (n=24).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.